The Impact of Clinical Variables and Dialysis Modality on Kynurenine Pathway Enzymes Expression
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27031313 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Izabela Zakrocka und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Medical University of Lublin, 20-090 Lublin, Poland. Hauptthemen laut MEDLINE: Kynurenine, Renal Dialysis, Transaminases, Renal Insufficiency, Chronic. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Lublin, Poland.
Abstract (Originalsprache)
Chronic kidney disease (CKD) and kidney failure significantly reduce patients’ quality of life and markedly increase cardiovascular risk and overall mortality. Disturbed metabolism of tryptophan (Trp) through kynurenine (KYN) pathway was implicated as an important factor in kidney damage and its complications. However, the expression of genes coding crucial enzymes of KYN pathway was not examined so far. The goal of the present study was to analyze the expression of Ido (indoleamine-2,3-dioxygenase), Kat1 (kynurenine aminotransferase 1), Kat2 (kynurenine aminotransferase 2), and Kmo (kynurenine-3-monooxygenase) genes in patients undergoing kidney failure with kidney replacement therapy (KFRT) treatment with either hemodiafiltration (HDF) or hemodialysis (HD) in relation to selected clinical and dialysis parameters. Our data imply that Ido, Kat1, and Kmo gene expression does not differ between KFRT patients with analyzed comorbidities, vascular access types, or diuresis occurrence. However, Ido and Kmo gene expression correlated with pre-dialysis concentration or reduction ratio (RR) of selected metabolites. Interestingly, patients treated with HDF manifested lower Kmo gene expression in comparison with patients treated by HD. Our study suggests that epigenetic factors do not exert noticeable impact on the KYN pathway enzymes expression in patients with KFRT. The advantageous effect of HDF vs. HD towards the KYN pathway genes expression has potential therapeutic implications, as it may reflect superiority of the former method in KFRT patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Medical University of Lublin, 20-090 Lublin, Poland.
- Institute of Health Sciences, The John Paul II Catholic University of Lublin, Konstantynów 1F Street, 20-708 Lublin, Poland.
- Department of Holistic Care and Management in Nursing, Medical University of Lublin, 20-081 Lublin, Poland.
- Department of Experimental and Clinical Pharmacology, Medical University of Lublin, 20-090 Lublin, Poland.
- Department of Internal Medicine IV, Nephrology and Hypertension, Medical University Innsbruck, 6020 Innsbruck, Austria.
ORCID-Profile: Izabela Zakrocka, Katarzyna Wicha-Komsta, Tomasz Kocki, Ewa M Urbańska, Andreas Kronbichler
Förderung
- Medical University of Lublin, Poland
Zitieren
APA
Zakrocka, I., Wicha-Komsta, K., Boczkowska, S., Kloc, R., Kocki, T., Urbańska, E. M., Załuska, W., & Kronbichler, A. (2026). The Impact of Clinical Variables and Dialysis Modality on Kynurenine Pathway Enzymes Expression. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27031313
Vancouver
Zakrocka I, Wicha-Komsta K, Boczkowska S, Kloc R, Kocki T, Urbańska EM, et al. The Impact of Clinical Variables and Dialysis Modality on Kynurenine Pathway Enzymes Expression. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27031313
BibTeX
@article{Zakrocka2026,
author = {Zakrocka, Izabela and Wicha-Komsta, Katarzyna and Boczkowska, Sylwia and Kloc, Renata and Kocki, Tomasz and Urbańska, Ewa M and Załuska, Wojciech and Kronbichler, Andreas},
title = {The Impact of Clinical Variables and Dialysis Modality on Kynurenine Pathway Enzymes Expression},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27031313}
}
EUVIMED